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Bovine adrenal tyrosine hydroxylase (TH) is isolated in a partially inhibited state with the feed-back inhibitors adrenaline and noradrenaline tightly 
coordinated to high-spin (S= 5/2) Fe(II1) at the active site. In addition to the charge-transfer interaction with iron, an additional charged group 
in the polypeptide chain, with an apparent p& of about 5.3 at 4”C, is involved in the binding of catecholamines. Protonation of this group increases 
the pseudo-first order rate constant for the dissociation of the TH-PH]noradrenaline complex more than lOO-fold at 4°C. At pH 7.0 and 3O”C, 
phosphorylation of Ser-40 causes a 6-fold increase in the rate constant for this dissociation. 
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1. INTRODUCTION 2. EXPERIMENTAL 
Tyrosine 3-monooxygenase (tyrosine hydroxylase 
(TH); EC 1.14.16.2) has recently received much atten- 
tion due to its key function in catecholamine biosyn- 
thesis and also its possible role in the pathogenesis of 
various neurological and psychiatric disorders [ 1,2]. 
Thus, detailed information on the catalytic mechanism 
and regulatory properties of the enzyme, as well as its 
molecular biology, is required in order to understand 
the modulation of neurotransmitter biosynthesis in the 
central nervous system in health and disease. 
2.1. Materials 
The catalytic subunit of bovine heart cyclic AMP-dependent pro- 
tein kinase was purified according to [9]. [y-32P]ATP and [‘H]NA 
were from Amersham International, England. Sephadex G-25 was 
from Pharmacia (Uppsala, Sweden). 
2.2. TH purification and phosphorylation 
The enzyme has been shown to be subject to a 
number of regulatory mechanisms in vivo. Particular 
emphasis has been put on long-term regulation at the 
level of gene expression and short-term regulation by 
phosphorylation/dephosphorylation [3,4]. The feed- 
back inhibition of TH in vitro by dopamine, 
noradrenaline (NA) and adrenaline has also been pro- 
posed to be of physiological significance [3,5,6], but 
the mechanism of this inhibition has so far not been 
unambiguously identified. Recently, we have presented 
evidence that catecholamines control the activity of TH 
in vitro by a direct coordination to iron at the active site 
[7,8]. However, little is yet known about the structural 
requirements for this association, the affinity of bin- 
ding, the rates of association/dissociation and its 
physiological significance. 
Bovine and rat adrenal TH were purified as described [7]. The 
phosphorylation of bovine TH was performed at 30°C in a mixture 
containing 0.1 mg/ml TH, 30 pg/ml catalytic subunit of bovine heart 
cyclic AMP-dependent protein kinase, 6.25 mM Mg(acetate)r. 
25 mM NaHepes, pH 7.0, 1 mM ATP, 1.25 mM dithiothreitol and 
1 mM EDTA. Similar experiments performed in the presence of 
[y-“P]ATP demonstrated that 0.6-0.7 mol phosphate/m01 enzyme 
subunit was incorporated into TH under these conditions. 
2.3. Assay of catecholamine r lease from TH 
The release of catecholamines from TH was assayed by rapid 
ultrafiltration. The enzyme (2.5 PM subunit) was incubated at either 
4 or 30°C as described below. After incubation, 100 ,~l of the enzyme 
was added to Ultrafree-MC low binding cellulose ultrafiltration units 
(type 10000 NMWL) from Millipore Corp. (Bedford, MA). Free and 
bound catecholamines were separated by centrifugation of the 
samples (4 min at 3000 x g.“). The catecholamines in the ultrafiltrate 
(14~1) were analyzed on a Hewlett-Packard 60 x 4.6 mm internal 
diameter (3 PM particle size) Cis reversed phase column, equipped 
with a precolumn and equilibrated with 10 mM sodium phosphate 
pH 3.9,25% methanol (v/v) and 0.007% sodium dodecylsulfate. The 
flow-rate was 0.7 ml/min and an LKB 2134 electrochemical detector 
was used for detection. 
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Alternatively, the endogenous catecholamines were first removed 
by incubation at pH 4.4 at 4°C for 15 min, followed by ammonium 
sulfate precipitation (50%), incubation with 0.1 CM [‘H]NA at pH 
7.5 and gel filtration (Sephadex G-25) at this pH. The release of 
[“HINA from the complex was assayed by ultrafiltration as described 
above. 
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3. RESULTS AND DISCUSSION 
3.1. pH-dependent release of catecholamines from TH 
The bovine adrenal enzyme as isolated contains tight- 
ly bound NA and adrenaline, i.e. about 0.35 mol 
catecholamine/mol subunit [S]. At neutral pH and 
4”C, the amines are released very slowly, but the rate 
is markedly increased below pH 6.0 (fig. 1A). When the 
endogenous catecholamines are removed by am- 
monium sulfate precipitation at pH 4.4, the enzyme 
rebinds labelled NA with high affinity at pH 7.0. The 
dissociation of the TH-[3H]NA complex revealed the 
same pH dependence as for the enzyme as isolated, 
with an S-fold increase from pH 6.0 to pH 4.0 (fig.lB). 
The pseudo-first order rate constant for the dissocation 
increased by a factor of 27 from pH 6.0 (k-1 = 3.4 x 
lo-’ s-l) to pH 4.8 (k-i = 9.0 x 10e4 s-l). The rates 
did not change when measured in the presence of excess 
(0.3 mM) unlabelled NA (data not shown). From 
fig.lB we can infer the nature of at least one of the 
bonds involved in this tight binding, i.e. a group with 
an apparent pKa of about 5.3 at 4°C. This value points 
to a carboxyl group involved in electrostatic interaction 
(forming a salt bridge) with the protonated amino 
group of NA (and other catecholamines). Our 
resonance Raman spectroscopic studies have revealed 
additional charge transfer interactions between 
catecholamines and the high-spin (S = 512) Fe(II1) [S]. 
This indicates that the distance for this interaction is of 
the same order as determined for the Fe(III)-oxyanion 
bond length in the [Fe(salen)catechol]- model complex 
(i.e. 1.8 A) [lo]. 
The pH-dependent release of catecholamines from 
TH is not restricted to the bovine adrenal enzyme. Very 
similar titration curves to those presented in fig. 1 were 
obtained with partially purified rat adrenal TH (results 
not shown). Furthermore, rat pheochromocytoma TH 
contains dopamine and NE which is released by acid 
treatment [ 111. It has also been reported that the rat 
striatal enzyme is inhibited by dopamine and activated 
by brief acid treatment [ 12,131. It was suggested that 
dopamine was ‘acting as a kind of catalyst’, since they 
were unable to observe any direct binding of the amine 
to the enzyme [13]. Our results (fig. l), however, sup- 
port the conclusion that this acid activation of rat 
striatum TH should rather be explained in terms of a 
reversible dissociation of enzyme-bound 
catecholamines. 
3.2. Effect of phosphorylation of Ser-40 on the release 
of catecholamines 
We have recently shown that bovine adrenal TH is 
selectively phosphorylated at Ser40 by cyclic AMP- 
dependent protein kinase (EC 2.7.1.37) [14] and that 
this phosphorylation is accompanied by an increased 
enzymatic activity and altered spectroscopic properties 
of the catecholamine-Fe(II1) complex at the active site 
364 
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Fig.1. Effect of pH on the release of catecholamines from bovine 
adrenal TH. (A) Release of endogenous NE (0) and adrenaline (0) 
from the enzyme as isolated. (B) Release of bound [‘H]NE from the 
enzyme after removal of endogenous catecholamines and binding of 
[‘H]NE. The TH concentration was 0.15 mg/ml (2.5 PM subunit) 
and the amount of catecholamines released after incubation for 
30 min at 4°C in 50 mM sodium acetate buffer was measured. 
[ 15,161. From fig.2 it is seen that the dissociation of the 
THj3H]NA complex at pH 7.0 and 30°C follows 
pseudo-first order kinetics, with a rate constant of 
k-i = 8.7 x 1O-5 s-l, and that phosphorylation causes 
a 6-fold increase in the rate constant (k-i = 5.1 x 
10e4 s-l). At acidic pH values, the effect of 
phosphorylation is less pronounced (data not shown). 
These findings explain our recent observations that 
phosphorylation of Ser-40 activates the enzyme by 
facilitating the reduction of the enzyme-bound Fe(II1) 
by the cofactor [16]. Thus, catecholamines have been 
shown to be competitive inhibitors of this cofactor [ 171 
and phosphorylation efficiently reverses this inhibition. 
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Fig.2. The effect of phosphorylation of Ser-40 on the rate of [‘H]NE 
release from TH. TH was phosphorylated as described in section 2.2 
(0). The control enzyme was incubated under identical conditions, 
but without Mg(acetate)z (0). Aliquots were taken out at intervals 
and free and bound [‘H]NA were determined as described in section 
2.3. 
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3.3. Conclusions 
Our findings have also other obvious implications 
for the interpretation of in vitro studies on TH. First, 
for the crude enzyme or enzyme isolated by published 
procedures, the active form represents only a fraction 
of the total, while the rest is inactive due to tightly 
bound catecholamines [7,8]. Secondly, the pH of the 
assay may also affect the concentration of active en- 
zyme. Thus, different pH optima have been found for 
the activity of the enzyme isolated with bound 
catecholamines, for acid-treated enzyme and for 
phosphorylated enzyme [17]. Finally, the stability of 
the catecholamine-coordinated enzyme towards inac- 
tivation seems to be higher than for the free enzyme 
1131. 
Based on estimates of the Kd value determined by 
equilibrium dialysis (i.e. 0.1-0.2 x 10e6 M at pH 7.0 
and 4°C) [18], it is evident that the dissociation (offi 
rate is several orders of magnitude slower than the on 
rate. The decrease in affinity by phosphorylation of 
Ser-40 seems to be brought about mainly by a 6-fold in- 
crease in the offrate (fig.2). Our data imply that the in- 
hibition of TH by physiological intracellular 
concentrations of catecholamines (i.e. in the range of 
0.5l.OpM) [19] is likely to be a sustained effect also 
under in vivo conditions. The dissociation rates found 
for the TH-[‘H]NA complex in vitro are in the same 
range as reported for the dissociation of the complex of 
cyclic AMP and the regulatory subunits of protein 
kinase A [20], and changes in these rate constants may 
have profound physiological effects. Taken together, 
our findings point to a key role of catecholamines in the 
regulation of their biosynthesis and activation of TH by 
phosphorylation at least partly is to be explained by a 
decreased affinity for inhibitory catecholamines. 
The inhibition of TH in vivo may be promoted by 
high intracellular levels of catecholamines, either as a 
result of physiological responses or induced phar- 
macologically. Thus, it may partly explain the side ef- 
fects and fluctuations in the clinical response observed 
in long-term treatment of Parkinson’s disease with the 
dopamine precursor L-DOPA (3,4_dihydroxyphenyl- 
alanine) [21]. In fact, the inhibition of TH would not 
be limited to the dopaminergic system, but would also 
include the noradrenergic neurons, and tryptophan 
hydroxylase may be inhibited by a similar mechanism 
[22]. A slow off rate for inhibitors of TH other than 
catecholamines, e.g. structurally related drugs [23], 
may also contribute to their sustained pharmacological 
effects. 
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